Brokers Offer Predictions for Corbus Pharmaceuticals Holdings Inc.’s FY2016 Earnings (CRBP)
Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) – Investment analysts at Cantor Fitzgerald issued their FY2016 earnings per share (EPS) estimates for shares of Corbus Pharmaceuticals Holdings in a report issued on Monday. Cantor Fitzgerald analyst E. Piros expects that the firm will post earnings per share of ($0.39) for the year. Cantor Fitzgerald has a “Buy” rating and a $17.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Corbus Pharmaceuticals Holdings’ FY2017 earnings at ($0.48) EPS.
Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last released its quarterly earnings data on Monday, August 15th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by $0.03. Corbus Pharmaceuticals Holdings had a negative return on equity of 107.10% and a negative net margin of 890.44%.
Separately, Aegis reaffirmed a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a research note on Sunday, August 21st.
Shares of Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) opened at 9.50 on Wednesday. The stock’s 50 day moving average is $6.37 and its 200 day moving average is $3.64. Corbus Pharmaceuticals Holdings has a 52-week low of $1.01 and a 52-week high of $10.78. The stock’s market capitalization is $415.61 million.
In other Corbus Pharmaceuticals Holdings news, insider Barbara White acquired 38,000 shares of the company’s stock in a transaction dated Wednesday, August 17th. The stock was bought at an average price of $3.15 per share, with a total value of $119,700.00. Following the completion of the transaction, the insider now directly owns 161,067 shares of the company’s stock, valued at $507,361.05. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Sean F. Moran acquired 30,800 shares of the company’s stock in a transaction dated Thursday, September 8th. The stock was acquired at an average cost of $5.12 per share, with a total value of $157,696.00. Following the transaction, the chief financial officer now directly owns 330,110 shares of the company’s stock, valued at $1,690,163.20. The disclosure for this purchase can be found here. Company insiders own 11.60% of the company’s stock.
Corbus Pharmaceuticals Holdings Company Profile
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases.
Receive News & Stock Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related stocks with our FREE daily email newsletter.